Table 1
From the following article
The growth and potential of human antiviral monoclonal antibody therapeutics
Wayne A Marasco & Jianhua Sui
Nature Biotechnology 25, 1421 - 1434 (2007) Published online: 7 December 2007
doi:10.1038/nbt1363
Table 1. Passive immunotherapy with convalescent human serum
| Year of study | Disease | Prophylaxis or treatment | Number of study subjects | Trend in benefit | Reference |
|---|---|---|---|---|---|
aOther studies refer to ref. 1. | |||||
bImmune BHF gamma globulin was used. | |||||
cHIV hyperimmune globulin was used. | |||||
| 1907 | Measles (Rubeola) | Prophylaxis | Unknown | Prevention. | 2 |
| 1918 | Measlesa | Prophylaxis | 1 | One child in a family of four children was given serum from the first infected child and was protected; the other two contracted measles. | 96 |
| 1918 | Measles | Prophylaxis | 4 | Prophylaxis was effective. | 96 |
| 1918 | 1918 Pandemic flu | Treatment | 56 | Early administration generally resulted in distinct improvement in clinical symptoms. | 9798 |
| 1923 | Varicella-Zoster virus | Prophylaxis | 42 | Seven contracted a mild form of the disease, 35 escaped without symptoms. | 99 |
| 1963b | Bolivian hemorrhagic fever | Treatment | 4 | Individuals recovered after 6–8 weeks. | 100 |
| 1959–1983 | Argentine hemorrhagic fever | Treatment | 4,433 | Mortality rate of 3.29% (versus 42.85% in individuals treated before convalescent plasma was used). | 101 |
| 1974–1978 | Argentine hemorrhagic fever | Treatment | 217 | 1.1% mortality rate of those treated with immune plasma. | 102 |
| 1969 | Lassa fever | Treatment | 1 | The individual recovered. | 103 |
| 1984 | Lassa fever | Prophylaxis and treatment | 27 | All study subjects given plasma on or before the 10th day survived with a rapid response to therapy. | 104 |
| 1995 | Ebola hemorrhagic fever | Treatment | 8 | 12.5% fatality rate (versus overall case fatality rate of 80%); inconclusive regarding neutralizing antibodies in convalescent blood. | 105 |
| 1993 | HIV-1 | Treatment of stage IV AIDS individuals | 63 | Randomized double-blind controlled trial. Study subjects were given 250 ml of HIV-immune plasma every 4 weeks. No significant toxicity and effect were found. | 106 |
| 1995 | HIV-1 | Treatment of symptomatic HIV infection | 86 | Randomized double-blind controlled trial. Study subjects were given 300 ml of plasma rich in anti-HIV-1 antibody every 14 days for 1 year. Clinical benefit was observed. | 107 |
| 2002c | HIV-1 | Prevention of vertical transmission in Uganda | 60 | Phase 1/2 trial showed it is safe, well tolerated and similar pharmacokinetic property as other immunoglobulin products. | 108 |
| 2003 | SARS | Treatment | 1 | Fever decreased after administration of convalescent plasma. | 109 |
| 2007 | Influenza A (H5N1) | Treatment | 1 | Viral load was reduced after infusion of plasma; the individual recovered. | 110 |